Staphylococcus epidermidis (S. epidermidis)

Staphylococcus epidermidis is a Gram-positive, coagulase-negative bacterium that is a ubiquitous commensal of the human skin and mucous membranes. While typically non-pathogenic in healthy individuals, it has emerged as a major opportunistic pathogen, particularly responsible for healthcare-associated infections involving indwelling medical devices such as intravenous catheters, prosthetic joints, and cardiac valves (StatPearls: NBK560494; NIH: PMC4184643). Its primary virulence factor is the ability to form dense, multilayered biofilms, which protect the bacteria from host immune responses and significantly limit the penetration and efficacy of traditional antibiotics (PubMed: 25033443). In clinical practice, S. epidermidis often exhibits multidrug resistance, most notably methicillin resistance (MRSE) mediated by the mecA gene, requiring treatment with glycopeptides or newer-generation antimicrobials (PubMed: 32644265). Therapeutic interventions focus on inhibiting bacterial cell wall synthesis, protein translation, or disrupting the biofilm matrix to resolve chronic infections.

Other names

Coagulase-negative StaphylococcusCoNSStaph epi

Antibiotics targeting this organism function through various pathways: glycopeptides (vancomycin) inhibit cell wall peptidoglycan synthesis; oxazolidinones (linezolid) and lincosamides (clindamycin) inhibit protein synthesis by binding to the 50S ribosomal subunit; and lipopeptides (daptomycin) cause rapid depolarization of the bacterial membrane (StatPearls: NBK560494; PubMed: 25033443).